In today's landscape of weight loss medications, individuals have a plethora of choices. Traditional options like Ozempic and Mounjaro remain popular, while alternatives such as Wegovy's new pill are gaining traction. For those who prefer a non-injection method, compounded versions are available online, providing flexibility in treatment.
Despite the effectiveness of existing medications, the introduction of CagriSema has sparked interest and debate within the weight loss community. This experimental GLP-1 variant is said to function differently than its predecessors and boasts potential power that may be double that of current options. Novo Nordisk is seeking FDA approval for CagriSema, aiming for a launch in December 2025.
Understanding CagriSema
CagriSema is a unique combination of semaglutide, the active ingredient found in Wegovy and Ozempic, and cagrilintide. According to Dr. Richard Siegel, co-director of the Diabetes and Lipid Center at Tufts Medical Center, this drug acts as both a GLP-1 agonist and an amylin agonist, enhancing the duration food remains in the stomach while helping to stabilize blood sugar levels.
If approved, CagriSema would mark the debut of a long-acting amylin agonist in the market, a significant milestone in weight management medications.
The excitement surrounding CagriSema stems from its anticipated superior results compared to existing GLP-1s. Preliminary research indicates that participants using CagriSema experienced an approximate weight loss of 21% of their body weight, significantly more than the 13.7% reduction associated with semaglutide and 20% with tirzepatide (Mounjaro, Zepbound).
Challenges Ahead
However, a recent trial comparing CagriSema with Zepbound revealed that expectations may have been overly optimistic. The REDEFINE 4 clinical trial, involving 809 participants, showed that those on CagriSema lost about 20.2% of their body weight, while Zepbound users achieved a 23.6% loss.
Experts were not surprised by these findings, as tirzepatide consistently ranks among the most effective weight-loss medications. Dr. Siegel noted that while CagriSema demonstrated meaningful weight loss, it did not surpass the results of Zepbound.
Despite the hurdles, the potential for CagriSema remains significant. Dr. Mir Ali, medical director at MemorialCare Surgical Weight Loss Center, suggests that if CagriSema gains FDA approval, the current evidence indicates it may not achieve the same level of popularity as other medications due to its mechanism of action.
A Vision for the Future
Looking ahead, Dr. Siegel envisions a more personalized approach to weight loss medications, where genetic and other individual characteristics may influence the effectiveness of different treatments. The introduction of diverse medications could foster healthy competition, ultimately leading to more affordable options for consumers.
